Clinical Cancer Research Joint Metastasis Research Society-AACR Conference on Metastasis Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Lorenzo, G.
Right arrow Articles by Ciardiello, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Lorenzo, G.
Right arrow Articles by Ciardiello, F.
Clinical Cancer Research Vol. 8, 3438-3444, November 2002
© 2002 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer1

Giuseppe Di Lorenzo, Giampaolo Tortora, Francesco P. D’Armiento, Gaetano De Rosa, Stefania Staibano, Riccardo Autorino, Massimo D’Armiento, Michele De Laurentiis, Sabino De Placido, Giuseppe Catalano, A. Raffaele Bianco and Fortunato Ciardiello2

Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica [G. D. L., G. T., M. D. L., S. D. P., A. R. B., F. C.] and Dipartimento di Scienze Biomorfologiche e Funzionali [F. P. D. A., G. D. R., S. S.], Università degli Studi di Napoli Federico II, 80131 Naples, and Clinica Urologica [R. A., M. D. A.] and Cattedra di Oncologia Medica, Dipartimento di Medicina Sperimentale [G. C.], Seconda Università degli Studi di Napoli, Naples, Italy

Purpose: The transforming growth factor {alpha}-epidermal growth factor receptor (EGFR) autocrine pathway has been implicated in prostate cancer cell growth. Amplification and/or overexpression of c-erbB-2, a receptor closely related to the EGFR, has been recently involved in prostate cancer progression. We investigated EGFR and c-erbB-2 expression in primary androgen-dependent and in advanced androgen-independent prostate cancer and their potential role as markers of disease progression.

Experimental Design: EGFR and c-erbB-2 expression were evaluated by immunohistochemistry in a consecutive series of 74 prostate cancer patients with the following characteristics: 29 patients (group 1) treated with radical prostatectomy; 29 patients (group 2) treated with luteinizing hormone-releasing hormone analogues and antiandrogen therapy followed by radical prostatectomy; and 16 patients with hormone-refractory metastatic disease. In all patients we evaluated: association between EGFR and/or c-erbB-2 expression and clinicopathological parameters; and disease-free survival according to EGFR and c-erbB-2 expression in univariate analysis (Kaplan-Meier product-limit method) and in multivariate analysis (Cox proportional hazards regression model).

Results: EGFR expression was found in 12 of 29 (41.4%) group 1 patients, in 22 of 29 (75.9%) group 2 patients (P < 0.0005), and in 16 of 16 (100%) metastatic patients (P < 0.005), whereas c-erbB-2 expression was found in 11 of 29 (37.9%) group 1, in 10 of 29 (34.5%) group 2 patients, and in 9 of 16 (56.3%) metastatic patients. A significant association was found between EGFR expression and a high Gleason score (P < 0.01) and between EGFR expression and higher serum prostate-specific antigen values (P < 0.02) in all groups of patients. Among the 58 patients treated with radical prostatectomy, 23 of 34 EGFR-positive patients (67.6%) relapsed, whereas only 2 of 24 EGFR-negative patients (8.3%) relapsed (P < 0.00004). c-erbB-2 expression did not significantly correlate with disease relapse (P = 0.07). In a Cox multivariate analysis, the only parameter with an independent prognostic effect on disease-free survival was EGFR expression (relative hazard, 11.23; P = 0.0014).

Conclusions: EGFR expression increases during the natural history of prostate cancer. Correlation with disease progression and hormone-refractory disease suggests that EGFR-targeted drugs could be of therapeutic relevance in prostate cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. L. Teixeira, R. Ribeiro, D. Cardoso, D. Pinto, F. Lobo, A. Fraga, F. Pina, F. Calais-da-Silva, and R. Medeiros
Genetic Polymorphism in EGF Is Associated with Prostate Cancer Aggressiveness and Progression-Free Interval in Androgen Blockade-Treated Patients
Clin. Cancer Res., June 1, 2008; 14(11): 3367 - 3371.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, and P. Viens
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
Ann. Onc., May 7, 2008; (2008) mdn174v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. I. Park, J. Zhang, K. A. Phillips, J. C. Araujo, A. M. Najjar, A. Y. Volgin, J. G. Gelovani, S.-J. Kim, Z. Wang, and G. E. Gallick
Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
Cancer Res., May 1, 2008; 68(9): 3323 - 3333.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra
Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies
Endocr. Rev., April 1, 2008; 29(2): 234 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. S. Lyons, S. Rao, W. Balkan, J. Faysal, C. A. Maiorino, and K. L. Burnstein
Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer
Mol. Endocrinol., March 1, 2008; 22(3): 597 - 608.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Domingo-Domenech, P. L. Fernandez, X. Filella, A. Martinez-Fernandez, R. Molina, E. Fernandez, A. Alcaraz, J. Codony, P. Gascon, and B. Mellado
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
Ann. Onc., February 1, 2008; 19(2): 269 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Beaudry, M. Nilsson, M. Rioth, D. Prox, D. Poon, L. Xu, P. Zweidler-Mckay, A. Ryan, J. Folkman, S. Ryeom, et al.
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium
Mol. Cancer Ther., February 1, 2008; 7(2): 418 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Schlomm, P. Kirstein, L. Iwers, B. Daniel, T. Steuber, J. Walz, F. H.K. Chun, A. Haese, J. Kollermann, M. Graefen, et al.
Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6579 - 6584.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Fizazi
The role of Src in prostate cancer
Ann. Onc., November 1, 2007; 18(11): 1765 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. Festuccia, G. L. Gravina, P. Muzi, R. Pomante, L. Ventura, R. L Vessella, C. Vicentini, and M. Bologna
Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer
Endocr. Relat. Cancer, September 1, 2007; 14(3): 601 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, et al.
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2023 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Mimeault, S. L. Johansson, G. Vankatraman, E. Moore, J.-P. Henichart, P. Depreux, M.-F. Lin, and S. K. Batra
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells
Mol. Cancer Ther., March 1, 2007; 6(3): 967 - 978.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al.
Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
L. Bonaccorsi, D. Nosi, M. Muratori, L. Formigli, G. Forti, and E. Baldi
Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines
J. Mol. Endocrinol., January 1, 2007; 38(1): 51 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. L. Kovar, M. A. Johnson, W. M. Volcheck, J. Chen, and M. A. Simpson
Hyaluronidase Expression Induces Prostate Tumor Metastasis in an Orthotopic Mouse Model
Am. J. Pathol., October 1, 2006; 169(4): 1415 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z. Li, M. Szabolcs, J. D. Terwilliger, and A. Efstratiadis
Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene
Carcinogenesis, May 1, 2006; 27(5): 1054 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. H. Koumakpayi, J.-S. Diallo, C. Le Page, L. Lessard, M. Gleave, L. R. Begin, A.-M. Mes-Masson, and F. Saad
Expression and Nuclear Localization of ErbB3 in Prostate Cancer.
Clin. Cancer Res., May 1, 2006; 12(9): 2730 - 2737.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Angelucci, G. L. Gravina, N. Rucci, D. Millimaggi, C. Festuccia, P. Muzi, A. Teti, C. Vicentini, and M. Bologna
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 197 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. Nanni, C. Priolo, A. Grasselli, M. D'Eletto, R. Merola, F. Moretti, M. Gallucci, P. De Carli, S. Sentinelli, A. M. Cianciulli, et al.
Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer
Mol. Cancer Res., February 1, 2006; 4(2): 79 - 92.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Mimeault and S. K. Batra
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies
Carcinogenesis, January 1, 2006; 27(1): 1 - 22.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C Festuccia, P Muzi, D Millimaggi, L Biordi, G L Gravina, S Speca, A Angelucci, V Dolo, C Vicentini, and M Bologna
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines
Endocr. Relat. Cancer, December 1, 2005; 12(4): 983 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. R. Stewart and C. A. O'Brian
Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells
Mol. Cancer Ther., May 1, 2005; 4(5): 726 - 732.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. K Oosterhoff, J A. Grootegoed, and L. J Blok
Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling
Endocr. Relat. Cancer, March 1, 2005; 12(1): 135 - 148.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. F Singer, G. Hudelist, W. Lamm, R. Mueller, K. Czerwenka, and E. Kubista
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors
Endocr. Relat. Cancer, December 1, 2004; 11(4): 861 - 869.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Shuch, M. Mikhail, J. Satagopan, P. Lee, H. Yee, C. Chang, C. Cordon-Cardo, S. S. Taneja, and I. Osman
Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer
J. Clin. Oncol., December 1, 2004; 22(23): 4725 - 4729.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
L BONACCORSI, S MARCHIANI, M MURATORI, V CARLONI, G FORTI, and E BALDI
Signaling Mechanisms That Mediate Invasion in Prostate Cancer Cells
Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 283 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bianco, R. Caputo, R. Caputo, V. Damiano, S. De Placido, C. Ficorella, S. Agrawal, A. R. Bianco, F. Ciardiello, and G. Tortora
Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer
Clin. Cancer Res., July 15, 2004; 10(14): 4858 - 4864.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Kim, H. Uehara, S. Yazici, R. R. Langley, J. He, R. Tsan, D. Fan, J. J. Killion, and I. J. Fidler
Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice
Cancer Res., June 15, 2004; 64(12): 4201 - 4208.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M.-T. Ling, X. Wang, D. T. Lee, P.C. Tam, S.-W. Tsao, and Y.-C. Wong
Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R)
Carcinogenesis, April 1, 2004; 25(4): 517 - 525.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. B. Singh and R. C. Harris
Epidermal Growth Factor Receptor Activation Differentially Regulates Claudin Expression and Enhances Transepithelial Resistance in Madin-Darby Canine Kidney Cells
J. Biol. Chem., January 30, 2004; 279(5): 3543 - 3552.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
W.A. Schulz, M. Burchardt, and M.V. Cronauer
Molecular biology of prostate cancer
Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q.-T. Le and A. J. Giaccia
HIF-{alpha}, a Gender Independent Transcription Factor
Clin. Cancer Res., July 1, 2003; 9(7): 2391 - 2393.
[Full Text] [PDF]

Home page
 Sci SignalHome page
A. M. Bode and Z. Dong
Mitogen-Activated Protein Kinase Activation in UV-Induced Signal Transduction
Sci. Signal., January 28, 2003; 2003(167): re2 - re2.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.